Defour A, Van der Meulen J H, Bhat R, Bigot A, Bashir R, Nagaraju K, Jaiswal J K
Center for Genetic Medicine Research, Children's National Medical Center, 111 Michigan Avenue NW, Washington, DC, USA.
Institut de Myologie, UM76 Université Pierre et Marie Curie, U974 INSERM, UMR7215 CNRS, GH Pitié-Salpétrière, 47 bd de l'Hôpital, Paris, France.
Cell Death Dis. 2014 Jun 26;5(6):e1306. doi: 10.1038/cddis.2014.272.
Dysferlin deficiency compromises the repair of injured muscle, but the underlying cellular mechanism remains elusive. To study this phenomenon, we have developed mouse and human myoblast models for dysferlinopathy. These dysferlinopathic myoblasts undergo normal differentiation but have a deficit in their ability to repair focal injury to their cell membrane. Imaging cells undergoing repair showed that dysferlin-deficit decreased the number of lysosomes present at the cell membrane, resulting in a delay and reduction in injury-triggered lysosomal exocytosis. We find repair of injured cells does not involve formation of intracellular membrane patch through lysosome-lysosome fusion; instead, individual lysosomes fuse with the injured cell membrane, releasing acid sphingomyelinase (ASM). ASM secretion was reduced in injured dysferlinopathic cells, and acute treatment with sphingomyelinase restored the repair ability of dysferlinopathic myoblasts and myofibers. Our results provide the mechanism for dysferlin-mediated repair of skeletal muscle sarcolemma and identify ASM as a potential therapy for dysferlinopathy.
dysferlin缺乏会损害受损肌肉的修复,但潜在的细胞机制仍不清楚。为了研究这一现象,我们建立了dysferlin病的小鼠和人类成肌细胞模型。这些患有dysferlin病的成肌细胞经历正常分化,但修复细胞膜局部损伤的能力存在缺陷。对正在进行修复的细胞进行成像显示,dysferlin缺乏会减少细胞膜上溶酶体的数量,导致损伤触发的溶酶体胞吐作用延迟并减少。我们发现受损细胞的修复不涉及通过溶酶体-溶酶体融合形成细胞内膜补丁;相反,单个溶酶体与受损细胞膜融合,释放酸性鞘磷脂酶(ASM)。在受损的dysferlin病细胞中,ASM分泌减少,用鞘磷脂酶进行急性治疗可恢复dysferlin病成肌细胞和肌纤维的修复能力。我们的结果提供了dysferlin介导的骨骼肌肌膜修复机制,并确定ASM是dysferlin病的一种潜在治疗方法。